Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. August 2023 08:00 ET | Quelle: Indaptus Therapeutics

Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer

NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients,...
15. Juni 2023 08:00 ET | Quelle: Indaptus Therapeutics

Indaptus Therapeutics to Participate in the Maxim Group Virtual Healthcare Conference

NEW YORK, June 15, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients,...
31. Mai 2023 08:30 ET | Quelle: Indaptus Therapeutics

Indaptus Therapeutics to Present at the Jefferies Healthcare Conference 2023

NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients,...
11. Mai 2023 07:00 ET | Quelle: Indaptus Therapeutics

Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced financial results for the first quarter ended March 31, 2023 and...
09. Mai 2023 08:00 ET | Quelle: Indaptus Therapeutics

Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform

NEW YORK, May 09, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today...
01. Mai 2023 08:00 ET | Quelle: Indaptus Therapeutics

Indaptus Therapeutics’ Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative...
20. April 2023 16:05 ET | Quelle: Indaptus Therapeutics

Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023

NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today...
19. April 2023 09:28 ET | Quelle: Indaptus Therapeutics

UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative...
19. April 2023 08:05 ET | Quelle: Indaptus Therapeutics

Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative...
17. April 2023 08:00 ET | Quelle: Indaptus Therapeutics

Indaptus Therapeutics Receives Brazilian Patent Allowance for Decoy Platform

NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today...

Vorherige Seite

Nächste Seite